Literature DB >> 25985117

A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.

Yanqiong Zhang1, Xiaodong Guo, Zhiwei Li, Boan Li, Zhiyan Li, Ruisheng Li, Qiuyan Guo, Lu Xiong, Lingxiang Yu, Jingmin Zhao, Na Lin.   

Abstract

MicroRNAs (miRNAs) contribute to a wide variety of human diseases by regulating gene expression, leading to imbalances in gene regulatory networks. To discover novel hepatocellular carcinoma (HCC)-related miRNA-target axes and to elucidate their functions, we here performed a systematic investigation combining biological data acquisition and integration, miRNA-target prediction, network construction, functional assay and clinical validation. As a result, a total of 117 HCC differentially expressed miRNAs were identified, and 728 high confident target genes of these miRNAs were collected. Then, the interaction network of target genes was constructed and 221 key nodes with topological importance in the network were identified according to their topological features including degree, node-betweenness, closeness and K-coreness. Among these key nodes, Cyclin D1 had the highest node-betweenness, implying its bottleneck role in the network. Luciferase reporter assay confirmed that miRNA-19a, which was one of HCC downregulated miRNAs, directly targeted Cyclin D1 in HCC cells. Moreover, miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression. Further clinical evidence also highlighted the prognostic potential of miR-19a/Cyclin D1 axis in HCC. In conclusion, this systematic investigation provides a framework to identify featured miRNAs and their target genes which are potent effectors in the occurrence and development of HCC. More importantly, miR-19a/Cyclin D1 axis might have promising applications as a therapeutic target and a prognostic marker for patients with HCC.

Entities:  

Keywords:  cyclin D1; gene regulatory network; hepatocellular carcinoma; microRNA; microRNA-19a; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25985117      PMCID: PMC4615594          DOI: 10.1080/15476286.2015.1022702

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  64 in total

1.  Recurrence of hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

2.  Bridging: Locating Critical Connectors in a Network.

Authors:  Thomas W Valente; Kayo Fujimoto
Journal:  Soc Networks       Date:  2010-07-01

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

4.  MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells.

Authors:  Teng Xu; Ying Zhu; Yujuan Xiong; Yi-Yuan Ge; Jing-Ping Yun; Shi-Mei Zhuang
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

5.  Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma.

Authors:  Rongrong Wei; Guo-Liang Huang; Mei-Yin Zhang; Bin-Kui Li; Hui-Zhong Zhang; Ming Shi; Xiao-Qian Chen; Long Huang; Qing-Ming Zhou; Wei-Hua Jia; X F Steven Zheng; Yun-Fei Yuan; Hui-Yun Wang
Journal:  Clin Cancer Res       Date:  2013-06-28       Impact factor: 12.531

6.  miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.

Authors:  Gang Shen; Hongyun Jia; Qiang Tai; Yanhao Li; Deji Chen
Journal:  Carcinogenesis       Date:  2012-10-20       Impact factor: 4.944

7.  Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Chi Young Ok; Zijun Y Xu-Monette; Alexandar Tzankov; Dennis P O'Malley; Santiago Montes-Moreno; Carlo Visco; Michael B Møller; Karen Dybkaer; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; J Han van Krieken; Maurilio Ponzoni; John P Farnen; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Ken H Young
Journal:  Cancer       Date:  2014-03-19       Impact factor: 6.860

8.  Modularity detection in protein-protein interaction networks.

Authors:  Tejaswini Narayanan; Merril Gersten; Shankar Subramaniam; Ananth Grama
Journal:  BMC Res Notes       Date:  2011-12-29

9.  Reactome knowledgebase of human biological pathways and processes.

Authors:  Lisa Matthews; Gopal Gopinath; Marc Gillespie; Michael Caudy; David Croft; Bernard de Bono; Phani Garapati; Jill Hemish; Henning Hermjakob; Bijay Jassal; Alex Kanapin; Suzanna Lewis; Shahana Mahajan; Bruce May; Esther Schmidt; Imre Vastrik; Guanming Wu; Ewan Birney; Lincoln Stein; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2008-11-03       Impact factor: 16.971

10.  The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics.

Authors:  Haiyuan Yu; Philip M Kim; Emmett Sprecher; Valery Trifonov; Mark Gerstein
Journal:  PLoS Comput Biol       Date:  2007-02-14       Impact factor: 4.475

View more
  14 in total

1.  Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Authors:  Yi Zhe; Yan Li; Dan Liu; Dong-Ming Su; Jin-Gang Liu; Hang-Yu Li
Journal:  Tumour Biol       Date:  2016-08-04

2.  Thrombospondin-1 and microRNA-1 expression in response to multiwalled carbon nanotubes in alveolar epithelial cells.

Authors:  M Pacurari; R Kafoury; T Turner; S Taylor; P B Tchounwou
Journal:  Environ Toxicol       Date:  2017-01-27       Impact factor: 4.119

3.  MiR-106b-5p Promotes Malignant Behaviors of Cervical Squamous Cell Carcinoma Cells by Targeting TIMP2.

Authors:  Huier Sun; Xuejun Chen
Journal:  Reprod Sci       Date:  2021-11-12       Impact factor: 3.060

4.  MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.

Authors:  Guifang Yu; Xuezhu Chen; Shudi Chen; Weipeng Ye; Kailian Hou; Min Liang
Journal:  J Transl Med       Date:  2016-05-05       Impact factor: 5.531

5.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

6.  miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.

Authors:  Xiaonian Cao; Senyan Lai; Fayong Hu; Guodong Li; Guihua Wang; Xuelai Luo; Xiangning Fu; Junbo Hu
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

Review 7.  Small but Heavy Role: MicroRNAs in Hepatocellular Carcinoma Progression.

Authors:  Erbao Chen; Xiaojing Xu; Ruiqi Liu; Tianshu Liu
Journal:  Biomed Res Int       Date:  2018-05-22       Impact factor: 3.411

8.  Blood-derived DNA methylation predictors of mortality discriminate tumor and healthy tissue in multiple organs.

Authors:  Yan Zhang; Melanie Bewerunge-Hudler; Matthias Schick; Barbara Burwinkel; Esther Herpel; Michael Hoffmeister; Hermann Brenner
Journal:  Mol Oncol       Date:  2020-06-22       Impact factor: 6.603

9.  Interplay of miRNAs and Canonical Wnt Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Xiaobo Nie; Yiran Liu; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2018-06-21       Impact factor: 5.810

10.  MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2.

Authors:  Ling-Xiang Yu; Bo-Lun Zhang; Mu-Yi Yang; Hu Liu; Chao-Hui Xiao; Shao-Geng Zhang; Rong Liu
Journal:  Onco Targets Ther       Date:  2019-07-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.